Brokerages Set Alphatec Holdings, Inc. (NASDAQ:ATEC) PT at $18.50

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $18.50.

A number of research firms have commented on ATEC. Wall Street Zen lowered shares of Alphatec from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Lake Street Capital upgraded shares of Alphatec to a “buy” rating and set a $18.00 target price for the company in a research note on Monday, June 16th. Barclays reissued an “overweight” rating and issued a $22.00 target price (up from $21.00) on shares of Alphatec in a report on Monday, August 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research report on Saturday, September 27th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Friday, August 1st.

Alphatec Stock Performance

Shares of NASDAQ:ATEC opened at $13.60 on Tuesday. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The business’s fifty day moving average price is $15.09 and its two-hundred day moving average price is $12.59. Alphatec has a fifty-two week low of $4.88 and a fifty-two week high of $16.70. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -12.04 and a beta of 1.05.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million for the quarter, compared to the consensus estimate of $178.85 million. During the same period in the previous year, the business posted ($0.29) earnings per share. The firm’s revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. As a group, analysts predict that Alphatec will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Craig E. Hunsaker sold 10,876 shares of Alphatec stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $15.33, for a total value of $166,729.08. Following the completion of the transaction, the executive vice president directly owned 1,389,142 shares of the company’s stock, valued at $21,295,546.86. The trade was a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Patrick Miles sold 100,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $13.96, for a total transaction of $1,396,000.00. Following the transaction, the chief executive officer owned 5,464,078 shares in the company, valued at approximately $76,278,528.88. This trade represents a 1.80% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 786,057 shares of company stock valued at $11,835,311 in the last 90 days. 22.80% of the stock is owned by corporate insiders.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of ATEC. Wealth Enhancement Advisory Services LLC raised its position in Alphatec by 301.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company’s stock worth $608,000 after purchasing an additional 45,027 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Alphatec by 38,433.3% in the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company’s stock valued at $228,000 after buying an additional 2,306 shares during the period. SG Americas Securities LLC raised its position in shares of Alphatec by 28.3% during the first quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company’s stock worth $577,000 after acquiring an additional 12,553 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in shares of Alphatec by 13.4% during the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company’s stock valued at $133,000 after acquiring an additional 1,552 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Alphatec by 6.9% in the first quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company’s stock valued at $1,508,000 after acquiring an additional 9,661 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.